205 related articles for article (PubMed ID: 2868762)
21. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
Kong DS; Yeo SH
Pharmatherapeutica; 1989; 5(6):371-9. PubMed ID: 2687894
[TBL] [Abstract][Full Text] [Related]
22. Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
Rajarethinam R; Dziuba J; Manji S; Pizzuti A; Lachover L; Keshavan M
World J Biol Psychiatry; 2009; 10(4 Pt 2):416-9. PubMed ID: 19492247
[TBL] [Abstract][Full Text] [Related]
23. The reversibility of "permanent" tardive dyskinesia.
Klawans HL; Tanner CM; Barr A
Clin Neuropharmacol; 1984; 7(2):153-9. PubMed ID: 6145520
[TBL] [Abstract][Full Text] [Related]
24. Akathisia: clinical phenomenology and relationship to tardive dyskinesia.
Kahn EM; Munetz MR; Davies MA; Schulz SC
Compr Psychiatry; 1992; 33(4):233-6. PubMed ID: 1353716
[TBL] [Abstract][Full Text] [Related]
25. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients.
Dixon L; Weiden PJ; Haas G; Sweeney J; Frances AJ
Compr Psychiatry; 1992; 33(2):121-2. PubMed ID: 1347498
[TBL] [Abstract][Full Text] [Related]
26. Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence.
Cavallaro R; Regazzetti MG; Mundo E; Brancato V; Smeraldi E
Neuropsychopharmacology; 1993 May; 8(3):233-9. PubMed ID: 8099483
[TBL] [Abstract][Full Text] [Related]
27. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.
Miller DD; McEvoy JP; Davis SM; Caroff SN; Saltz BL; Chakos MH; Swartz MS; Keefe RS; Rosenheck RA; Stroup TS; Lieberman JA
Schizophr Res; 2005 Dec; 80(1):33-43. PubMed ID: 16171976
[TBL] [Abstract][Full Text] [Related]
28. Is tardive dyskinesia a unique disorder?
Marsden CD
Psychopharmacology Suppl; 1985; 2():64-71. PubMed ID: 2860661
[TBL] [Abstract][Full Text] [Related]
29. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G; Annable L; Campbell W
J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
[TBL] [Abstract][Full Text] [Related]
30. Fluphenazine decanoate and tardive dyskinesia.
Schiff AA
Am J Psychiatry; 1982 Jul; 139(7):969-70. PubMed ID: 6124136
[No Abstract] [Full Text] [Related]
31. Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology.
Wistedt B; Ranta J
Acta Psychiatr Scand; 1983 Jun; 67(6):378-88. PubMed ID: 6349256
[TBL] [Abstract][Full Text] [Related]
32. The effect of attention/information processing impairment of tardive dyskinesia and neuroleptics in chronic schizophrenics.
Spohn HE; Coyne L
Brain Cogn; 1993 Sep; 23(1):28-39. PubMed ID: 8105820
[TBL] [Abstract][Full Text] [Related]
33. Biological determinants and risk factors for tardive dyskinesia in schizophrenia.
Sandyk R
Int J Neurosci; 1993; 69(1-4):35-51. PubMed ID: 7916008
[TBL] [Abstract][Full Text] [Related]
34. Tardive dyskinesia and type II schizophrenia.
Davis EJ; Borde M; Sharma LN
Br J Psychiatry; 1992 Feb; 160():253-6. PubMed ID: 1347240
[TBL] [Abstract][Full Text] [Related]
35. Neurodevelopmental origins of tardivelike dyskinesia in schizophrenia patients and their siblings.
Ismail B; Cantor-Graae E; McNeil TF
Schizophr Bull; 2001; 27(4):629-41. PubMed ID: 11824489
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia.
Achalia RM; Chaturvedi SK; Desai G; Rao GN; Prakash O
Asian J Psychiatr; 2014 Jun; 9():31-5. PubMed ID: 24813033
[TBL] [Abstract][Full Text] [Related]
37. Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology.
Wegner JT; Catalano F; Gibralter J; Kane JM
Arch Gen Psychiatry; 1985 Sep; 42(9):860-5. PubMed ID: 2864029
[TBL] [Abstract][Full Text] [Related]
38. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.
Morgenstern H; Glazer WM
Arch Gen Psychiatry; 1993 Sep; 50(9):723-33. PubMed ID: 8102845
[TBL] [Abstract][Full Text] [Related]
39. Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review.
Domino EF
Psychopharmacology Suppl; 1985; 2():217-23. PubMed ID: 2860660
[TBL] [Abstract][Full Text] [Related]
40. Cognitive impairment in tardive dyskinesia.
Wegner JT; Kane JM; Weinhold P; Woerner M; Kinon B; Lieberman J
Psychiatry Res; 1985 Dec; 16(4):331-7. PubMed ID: 2868476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
